feed,title,long_url,short_url
Benzinga,Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint,https://benzinga.com/general/biotech/21/05/21192127/idera-will-not-continue-tilsotolimodipilimumab-combo-melanoma-trial-into-os-primary-endpoint,https://j.mp/3wlrNyj
